2. Academic Validation
  3. In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

  • Antimicrob Agents Chemother. 2019 May 24;63(6):e00470-19. doi: 10.1128/AAC.00470-19.
Amit Kaushik 1,  Nicole C Ammerman 1,  Olumide Martins 1,  Nicole M Parrish 2,  Eric L Nuermberger 3
Affiliations

Affiliations

  • 1 Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • 2 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • 3 Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA enuermb@jhmi.edu.
PMID: 30962331 DOI: 10.1128/AAC.00470-19
Abstract

Tigecycline is used in multidrug regimens for salvage therapy of Mycobacterium abscessus infections but is often poorly tolerated and has no oral formulation. Here, we report similar in vitro activity of two newly approved Tetracycline analogs, omadacycline and eravacycline, against 28 drug-resistant clinical isolates of M. abscessus complex. Since omadacycline and eravacycline appear to be better tolerated than tigecycline and since omadacycline is also formulated for oral dosing, these Tetracycline analogs may represent new treatment options for M. abscessus infections.

Keywords

Mycobacterium abscessus; drug susceptibility assay; eravacycline; omadacycline; tetracyclines; tigecycline.

Figures
Products